Sansure Biotech Inc. (688289.SS)
CNY 19.51
(-1.37%)
CNY 19.51
(-1.37%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 363.72 Million CNY | -81.22% |
| 2022 | 1.93 Billion CNY | -13.64% |
| 2021 | 2.24 Billion CNY | -14.29% |
| 2020 | 2.61 Billion CNY | 6527.9% |
| 2019 | 39.47 Million CNY | 483.82% |
| 2018 | 6.76 Million CNY | 163.47% |
| 2017 | -10.65 Million CNY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 81.02 Million CNY | 26.61% |
| 2024 Q2 | 75.68 Million CNY | -6.6% |
| 2024 Q3 | 38.72 Million CNY | -48.84% |
| 2023 Q2 | 31.66 Million CNY | -47.24% |
| 2023 FY | 363.72 Million CNY | -81.22% |
| 2023 Q1 | 60.01 Million CNY | -82.27% |
| 2023 Q3 | 208.04 Million CNY | 557.06% |
| 2023 Q4 | 63.99 Million CNY | -69.24% |
| 2022 Q4 | 338.43 Million CNY | -28.52% |
| 2022 Q2 | 473.06 Million CNY | -27.43% |
| 2022 Q1 | 651.86 Million CNY | 34.25% |
| 2022 Q3 | 473.43 Million CNY | 0.08% |
| 2022 FY | 1.93 Billion CNY | -13.64% |
| 2021 Q1 | 622.1 Million CNY | 3.03% |
| 2021 Q2 | 498.78 Million CNY | -19.82% |
| 2021 FY | 2.24 Billion CNY | -14.29% |
| 2021 Q4 | 485.55 Million CNY | -23.68% |
| 2021 Q3 | 636.24 Million CNY | 27.56% |
| 2020 FY | 2.61 Billion CNY | 6527.9% |
| 2020 Q4 | 603.78 Million CNY | -22.69% |
| 2020 Q1 | 193.07 Million CNY | 826.22% |
| 2020 Q2 | 1.03 Billion CNY | 437.98% |
| 2020 Q3 | 781.02 Million CNY | -24.81% |
| 2019 FY | 39.47 Million CNY | 483.82% |
| 2019 Q3 | 10.3 Million CNY | 16.14% |
| 2019 Q2 | 8.87 Million CNY | 1740.53% |
| 2019 Q1 | -540.72 Thousand CNY | 0.0% |
| 2019 Q4 | 20.84 Million CNY | 102.33% |
| 2018 FY | 6.76 Million CNY | 163.47% |
| 2017 FY | -10.65 Million CNY | 0.0% |